Ozempic vs Mounjaro: Single vs Dual Incretin Design

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The PlexusDx Education Hub follows how GLP-1 medicines, compounded weight-management protocols, and the genetics beneath them connect. Explore the full Peptides & GLP-1 library.

This comparison is editorially independent. PlexusDx holds no commercial relationship with Novo Nordisk or Eli Lilly, and neither manufacturer sponsored or reviewed this page.

Shoppers often treat Ozempic and Mounjaro as interchangeable, yet the two sit at different points on the incretin spectrum: one engages a single hormone receptor, the other engages two. That single design choice shapes their approved uses, their trial records, and the way a clinician reasons about each. Everything below reflects publicly available information as of April 2026.

Two incretin strategies inside one drug class

Ozempic is a selective glucagon-like peptide-1 (GLP-1) receptor agonist from Novo Nordisk. Mounjaro is a dual GIP and GLP-1 receptor agonist from Eli Lilly. Both belong to the incretin family, but the tirzepatide molecule in Mounjaro recruits a second receptor arm that semaglutide leaves untouched.

How the single- and dual-agonist designs diverge

Each compound activates the GLP-1 receptor across the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose excursions, and amplifying satiety signaling. Mounjaro layers agonism at the glucose-dependent insulinotropic polypeptide receptor on top of that, and that added GIP activity is the defining molecular difference between the two in this category.

Where each earned its FDA label

Ozempic was FDA-approved for type 2 diabetes in 2017 and its active ingredient has been widely studied for weight management. Mounjaro was FDA-approved for type 2 diabetes in 2022; the same tirzepatide molecule is also approved as Zepbound for chronic weight management. Those label boundaries dictate how each can be prescribed and whether insurance covers it.

Reading the two trial programs

Ozempic and the SUSTAIN studies

Semaglutide was evaluated in the SUSTAIN program for glycemic and cardiovascular outcomes, establishing the GLP-1 selective profile that Ozempic is known for.

Mounjaro and the SURPASS studies

Tirzepatide was evaluated in the SURPASS program, which included a head-to-head comparison against semaglutide 1 mg in type 2 diabetes. Because populations, doses, and primary endpoints differ between programs, the honest read is per-trial rather than a sweeping declaration of a winner.

Tolerability and the shared class warning

Both carry the GLP-1 class boxed warning tied to thyroid C-cell tumor risk seen in rodent studies. The most frequent side effects for either compound are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, and they tend to peak during dose escalation. Serious events reported across the class include pancreatitis, gallbladder problems, and acute kidney injury during dehydration.

What the monthly numbers look like

At U.S. list price as of April 2026, Ozempic runs approximately $968–$1,029 per month (Novo Nordisk published pricing) and Mounjaro approximately $1,069 per month (Eli Lilly published pricing). Actual out-of-pocket cost hinges on insurance coverage, manufacturer savings cards, the specific FDA indication written on the prescription, and whether a compounded option is available through a licensed compounding pharmacy pathway.

The genetics underneath both incretin arms

Whichever compound a provider selects, the upstream genetic architecture is the same. Variants in GIPR influence the GIP arm that tirzepatide recruits, while GLP1R and FTO shape baseline appetite regulation, satiety signaling, and adiposity set-point. These are pathway-level variants; they do not predict response to any single medicine, but they do describe the metabolic terrain a compound has to work on.

PlexusDx offers semaglutide through its Weight Management Protocols, including the Semaglutide protocol. What distinguishes the PlexusDx approach is that upstream genetic context. Before any GLP-1 pathway protocol begins, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including GIPR, FTO variants that shape your baseline incretin, appetite, and energy-balance biology. Reading that profile alongside a protocol is the test before you invest approach, turning guesswork into an informed conversation with your provider.

Related reading on PlexusDx: Ozempic for PCOS, Ozempic on Line, Cheap Ozempic, Ozempic Price without Insurance.

Disclaimer: This article is educational. PlexusDx offers semaglutide through its Weight Management Protocols, and this page covers the mechanism, evidence, and genetic context that inform any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare formats inside the Weight Management Protocols collection, or start upstream with the Precision Peptide Genetic Test to understand your incretin pathway biology first.

Frequently Asked Questions about Ozempic and Mounjaro

Is Mounjaro just a stronger version of Ozempic?

Not quite. Mounjaro contains tirzepatide, a dual GIP and GLP-1 agonist, while Ozempic contains semaglutide, a GLP-1-selective agonist. The difference is the number of receptor arms engaged, not simply a higher dose of the same molecule. Their approved indications and trial programs also differ, so they are distinct compounds.

Can I switch between the two?

Switching between GLP-1 medicines is a clinical decision that depends on your indication, tolerance, response, and coverage. Because Ozempic and Mounjaro use different active ingredients and dosing schedules, any transition should be planned and supervised by a prescriber rather than attempted independently based on a comparison article like this one.

Does the Precision Peptide Genetic Test say which one will work better?

No. The test does not predict response to Ozempic, Mounjaro, or any medication. It maps pathway-level variants such as GIPR, and FTO that describe your baseline incretin and appetite biology, giving you and your provider upstream context that applies no matter which compound is eventually prescribed.

Why is Mounjaro priced higher at list?

List prices reflect manufacturer decisions rather than a direct measure of value, and as of April 2026 Mounjaro carries a higher published monthly figure than Ozempic. What you actually pay depends far more on insurance, savings-card eligibility, the indication on your prescription, and whether a compounded pathway applies.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.